GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Asensus Surgical Inc (AMEX:ASXC) » Definitions » Capex-to-Operating-Cash-Flow

Asensus Surgical (Asensus Surgical) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Asensus Surgical Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Asensus Surgical's Capital Expenditure for the three months ended in Dec. 2023 was $-0.07 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $-13.37 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Asensus Surgical Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Asensus Surgical's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asensus Surgical Capex-to-Operating-Cash-Flow Chart

Asensus Surgical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Asensus Surgical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Asensus Surgical's Capex-to-Operating-Cash-Flow

For the Medical Devices subindustry, Asensus Surgical's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Asensus Surgical's Capex-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Asensus Surgical's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Asensus Surgical's Capex-to-Operating-Cash-Flow falls into.



Asensus Surgical Capex-to-Operating-Cash-Flow Calculation

Asensus Surgical's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.561) / -63.627
=N/A

Asensus Surgical's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.073) / -13.374
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Asensus Surgical  (AMEX:ASXC) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Asensus Surgical Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Asensus Surgical's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Asensus Surgical (Asensus Surgical) Business Description

Traded in Other Exchanges
Address
1 TW Alexander Drive, Suite 160, Durham, NC, USA, 27703
Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.
Executives
Starling William N Jr director 2300 BUCKSKIN ROAD, POCATELLO ID 83201
Andrea Biffi director C/O SOFAR SPA, VIA FIRENZE 40, TREZZANO ROSA (MI) L6 20060
Elizabeth Kwo director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
David Bruce Milne director ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Kevin J Hobert director 343 STATE STREET, ROCHESTER NY 14650
Fernando Anthony C. J. officer: Chief Technology Officer 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Rampertab Shameze officer: EVP, Chief Financial Officer C/O ZOMEDICA PHARMACEUTICALS CORP., 3928 VARSITY DRIVE, ANN ARBOR MI 48108
Brett Farabaugh officer: Interim CFO 108 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
Joseph P Slattery officer: EVP and CFO C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Eric A Smith officer: Chief Commercial Officer 7 CALEB CIRCLE, SAN ANTONIO TX 78258
Todd Pope director, officer: President and CEO C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713
Willam N Kelley director MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Sofar, S.p.a 10 percent owner VIA FIRENZE 40, TREZZANO ROSA L6 20060
Andrew N Schiff director, 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022

Asensus Surgical (Asensus Surgical) Headlines

From GuruFocus

TransEnterix and Butterfly Among Medtech M&A Opportunities

By Barry Cohen Barry Cohen 12-23-2020